Lichen Planopilaris Responsive to a Novel Phytoactive Botanical Treatment: A Case Series

Dermatology and Therapy - Tập 12 - Trang 1697-1710 - 2022
Sanusi Umar1,2,3, Petrina Kan4, Marissa J. Carter5, Paul Shitabata1,2,6, Myroslava Novosilska7
1Department of Medicine, University of California at Los Angeles, Los Angeles, (USA)
2Division of Dermatology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, USA
3Dr. U Hair and Skin Clinic, Manhattan Beach, USA
4Department of Molecular Biology, University of California at Los Angeles, Los Angeles, USA
5Strategic Solutions, Inc., Bozeman, USA
6Dermatopathology Institute, Torrance, USA
7Department of Dermatology and Oncology, Aesthetic Medical Clinic Myroslava Novosilska, Lviv, Ukraine

Tóm tắt

Lichen planopilaris (LPP) is characterized by chronic scarring alopecia that is progressive and typically refractory to therapy. Current drug treatments are suboptimal and not applicable for long-term use because of the high potential for adverse effects, warranting safer and more effective treatment alternatives. Based on our previous success in treating a patient with central centrifugal cicatricial alopecia using a topical botanical formulation (Gashee), we reviewed records of four patients with biopsy-proven LPP treated with the topical formulation alone or in combination with its oral preparation. Three patients had failed previous treatment with intralesional steroid injections, topical minoxidil, tacrolimus, and clobetasol. Physical examination and photographic documentation were also used as outcome measures. Treatment duration with the botanical formulations ranged from 6 weeks to 9.5 months. All patients showed overall improvement in surrogate indicators of LPP activity as evidenced by the disappearance of symptoms (pruritus, tenderness, scalp irritation, and hair shedding), improvement in hair growth, and reduction in redness. All reported a high satisfaction level and no adverse effects. Patients with treatment-refractory LPP responded to a novel botanical treatment. To the best of our knowledge, this is the first published report of LPP responding to a plant-based natural treatment. Further evaluation of this treatment in a controlled trial with a larger number of patients is warranted. Lichen planopilaris is a chronic and progressive condition, most commonly affecting middle-aged women. It results in scalp inflammation, scarring, and ultimately permanent hair loss. Treatments are typically ineffective in the long term and are associated with side effects that limit their use. We report success in treating four patients using a new botanical formulation called Dr. UGro Gashee as the sole therapy for a duration ranging from 6 weeks to 9.5 months. The treatment was administered topically or in combination with its oral formulation. All the patients showed cessation of disease progression with significant hair regrowth. They also reported complete resolution of scalp itch, tenderness, and irritation, with no adverse effects. Our report is the first published study of lichen planopilaris responding to a plant-based natural treatment and warrants further evaluation in larger controlled trials.

Tài liệu tham khảo

Errichetti E, Figini M, Croatto M, Stinco G. Therapeutic management of classic lichen planopilaris: a systematic review. Clin Cosmet Investig Dermatol. 2018;11:91–102.

Rongioletti F, Christana K. Cicatricial (scarring) alopecias: an overview of pathogenesis, classification, diagnosis, and treatment. Am J Clin Dermatol. 2012;13(4):247–60.

Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol. 2017;16(11):1140–2.

Randolph MJ, Salhi WA, Tosti A. Lichen planopilaris and low-level light therapy: four case reports and review of the literature about low-level light therapy and lichenoid dermatosis. Dermatol Ther (Heidelb). 2020;10(2):311–9.

Bolanča Ž, Goren A, Getaldić-Švarc B, Vučić M, Šitum M. Platelet-rich plasma as a novel treatment for lichen planopillaris. Dermatol Ther. 2016;29(4):233–5.

Umar S, Carter MJ. A multimodal hair-loss treatment strategy using a new topical phytoactive formulation: a report of five cases. Case Rep Dermatol Med. 2021;2021:6659943.

Sundberg JP, Hordinsky MK, Bergfeld W, et al. Cicatricial Alopecia Research Foundation meeting, May 2016: progress towards the diagnosis, treatment and cure of primary cicatricial alopecias. Exp Dermatol. 2018;27(3):302–10.

Jordan CS, Chapman C, Kolivras A, Roberts JL, Thompson NB, Thompson CT. Clinicopathologic and immunophenotypic characterization of lichen planopilaris and central centrifugal cicatricial alopecia: a comparative study of 51 cases. J Cutan Pathol. 2020;47(2):128–34.

Tavakolpour S, Mahmoudi H, Abedini R, Kamyab Hesari K, Kiani A, Daneshpazhooh M. Frontal fibrosing alopecia: an update on the hypothesis of pathogenesis and treatment. Int J Womens Dermatol. 2019;5(2):116–23.

Yang CC, Khanna T, Sallee B, Christiano AM, Bordone LA. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther. 2018;31(6): e12656.

Mirmirani P, Karnik P. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol. 2009;145(12):1363–6.

Imanishi H, Ansell DM, Chéret J, et al. Epithelial-to-mesenchymal stem cell transition in a human organ: lessons from lichen planopilaris. J Invest Dermatol. 2018;138(3):511–9.

McPhie ML, Wang A, Molin S, Herzinger T. Lichen planopilaris induced by infliximab: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20901967.

Soma T, Tsuji Y, Hibino T. Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle. J Invest Dermatol. 2002;118(6):993–7.

Kim HY, Park EJ, Joe EH, Jou I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol. 2003;171(11):6072–9.

Ashrafizadeh M, Rafiei H, Mohammadinejad R, Afshar EG, Farkhondeh T, Samarghandian S. Potential therapeutic effects of curcumin mediated by JAK/STAT signaling pathway: a review. Phytother Res. 2020;34(8):1745–60. https://doi.org/10.1002/ptr.6642.

Zhao HM, Xu R, Huang XY et al. Curcumin suppressed activation of dendritic cells via JAK/STAT/SOCS signal in mice with experimental colitis. Front Pharmacol. 2016;7:455. Published 2016 Nov 25. https://doi.org/10.3389/fphar.2016.00455

Hu Y, Liang H, Du Y, Zhu Y, Wang X. Curcumin inhibits transforming growth factor-beta activity via inhibition of Smad signaling in HK-2 cells. Am J Nephrol. 2010;31(4):332–41.

Pan Y, Zhao D, Yu N, et al. Curcumin improves glycolipid metabolism through regulating peroxisome proliferator activated receptor γ signalling pathway in high-fat diet-induced obese mice and 3T3-L1 adipocytes. R Soc Open Sci. 2017;4(11): 170917.

Jacob A, Wu R, Zhou M, Wang P. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res. 2007;2007:89369.

Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res. 2012;56(3):454–65.

Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research [published correction appears in Altern Med Rev. 2009 Sep; 14:277]. Altern Med Rev. 2009;14:141–53.

Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res. 1999;39:41–7.

Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010;292(2):197–207.

Bose S, Banerjee S, Mondal A et al. Targeting the JAK/STAT signaling pathway using phytocompounds for cancer prevention and therapy. Cells. 2020;9(6):1451. Published 2020 Jun 11. https://doi.org/10.3390/cells9061451

Dinesh Babu V, Suresh Kumar A, Sudhandiran G. Diosgenin inhibits TGF-β1/Smad signaling and regulates epithelial mesenchymal transition in experimental pulmonary fibrosis. Drug Chem Toxicol. 2020;1–12.

Mohammad-Sadeghipour M, Mahmoodi M, Noroozi Karimabad M, Mirzaei MR, Hajizadeh MR. Diosgenin and 4-hydroxyisoleucine from fenugreek are regulators of genes involved in lipid metabolism in the human colorectal cancer cell line SW480. Cell J. 2021;22(4):514–22.

Jung D-H, Park H-J, Byun H-E, et al. Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, Nf-κb and AP-1 activation. Int Immunopharmacol. 2010;10:1047–54.

Chowdhury AA, Gawali NB, Munshi R, Juvekar AR. Trigonelline insulates against oxidative stress, proinflammatory cytokines and restores BDNF levels in lipopolysaccharide induced cognitive impairment in adult mice. Metab Brain Dis. 2018;33:681–91.

Moers-Carpi M. Influence of nutritive factors on hair growth. Aktuelle Dermatol. 2011;37:171–5.

Cai B, Zhang Y, Wang Z, et al. Therapeutic potential of diosgenin and its major derivatives against neurological diseases: recent advances. Oxid Med Cell Longev. 2020;2020:3153082.

Tang SN, Fu J, Shankar S, Srivastava RK. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS ONE. 2012;7(2): e31067.

Farooqi AA, Pinheiro M, Granja A et al. EGCG mediated targeting of deregulated signaling pathways and non-coding RNAs in different cancers: focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways. Cancers (Basel). 2020;12(4):951. Published 2020 Apr 12. https://doi.org/10.3390/cancers12040951

Liu Y, Zhao B, Mao G, et al. Epigallocatechin-3-O-gallate, a green tea polyphenol, induces expression of pim-1 kinase via PPARγ in human vascular endothelial cells. Cardiovasc Toxicol. 2013;13(4):391–5. https://doi.org/10.1007/s12012-013-9220-4.

Ohishi T, Goto S, Monira P, Isemura M, Nakamura Y. Anti-inflammatory action of green tea. Antiinflamm Antiallergy Agents Med Chem. 2016;15(2):74–90.

Min SY, Yan M, Kim SB, et al. Green tea epigallocatechin-3-gallate suppresses autoimmune arthritis through indoleamine-2,3-dioxygenase expressing dendritic cells and the nuclear factor, erythroid 2-like 2 antioxidant pathway. J Inflamm (Lond). 2015;12:53. https://doi.org/10.1186/s12950-015-0097-9.

Harries MJ, Meyer K, Chaudhry I, et al. Lichen planopilaris is characterized by immune privilege collapse of the hair follicle’s epithelial stem cell niche. J Pathol. 2013;231(2):236–47.

Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol. 2009;129(5):1243–57.

Tsuji Y, Denda S, Soma T, Raftery L, Momoi T, Hibino T. A potential suppressor of TGF-beta delays catagen progression in hair follicles. J Investig Dermatol Symp Proc. 2003;8(1):65–8.

Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–6.

Thông tin
Thông tin xuất bản

Dermatology and Therapy

Tập 12

1697-1710

Thông tin tác giả